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Sialylated glycans serve as cell surface attachment factors for a
broad range of pathogens.We report an atypical example,where
desialylation increases cell surface binding and infectivity of
adeno-associated virus (AAV) serotype 9, a human parvovirus
isolate. Enzymatic removal of sialic acid, but not heparan sulfate
or chondroitin sulfate, increased AAV9 transduction regardless
of cell type. Viral binding and transduction assays on mutant
Chinese hamster ovary (CHO) cell lines defective in various
stages of glycan chain synthesis revealed a potential role for core
glycan residues under sialic acid in AAV9 transduction. Treat-
ment with chemical inhibitors of glycosylation and competitive
inhibition studies with different lectins suggest that N-linked
glycans with terminal galactosyl residues facilitate cell surface
binding and transduction byAAV9. In corollary, resialylation of
galactosylated glycans on the sialic acid-deficient CHO Lec2
cell linewith different sialyltransferases partially blockedAAV9
transduction. Quantitative analysis of AAV9 binding to paren-
tal, sialidase-treated or sialic acid-deficient mutant CHO cells
revealed a 3–15-fold increase in relative binding potential of
AAV9particles upon desialylation. Finally, pretreatment of well
differentiated human airway epithelial cultures and intranasal
instillation of recombinant sialidase in murine airways en-
hanced transduction efficiency of AAV9 by >1 order of magni-
tude. Taken together, the studies described herein provide a
molecular basis for low infectivity of AAV9 in vitro and a bio-
chemical strategy to enhance gene transfer by AAV9 vectors in
general.
Cell surface glycans have been shown to play a critical role
in the infectious pathways of viruses (1). Detailed studies of
virus-glycan interactions have yielded significant insight into
mechanisms underlying emergence and transmission of viral
pathogens in different hosts. Among various glycolipids, glyco-
proteins, or proteoglycans anchored to the plasma membrane,
sialylated glycans and heparan sulfate proteoglycans appear to
serve as predominant substrates for viral attachment to the cell
surface. For instance, heparan sulfate serves as a primary
receptor for Herpesviridae (2) as well as certain adenoviruses
(3) and parvoviruses (4, 5). Interactions between sialylated
glycans and members of the Orthomyxoviridae (6), Reoviri-
dae (7), Polyomaviridae (8) families and certain parvoviruses
are also well known (9–11).
Adeno-associated viruses (AAV)2 are small, single-stranded
DNA viruses that belong to the genusDependovirus of the Par-
voviridae family (12). Recombinant AAV vectors, by virtue of
their lack of pathogenicity and low immunogenicity, are cur-
rently being evaluated as lead candidates in clinical gene ther-
apy trials (13). The discovery of a large number of AAV isolates
over the past decade has accelerated efforts to exploit tissue
tropisms displayed by different strains for therapeutic gene
transfer applications (14, 15). Successful translation from
bench to bedside will require a thorough understanding of
molecular mechanisms underlying AAV infection. As with
other viruses, attachment to cell surface glycans constitutes the
first step in the AAV infectious pathway. For instance, several
AAV serotypes have been shown to bind heparan sulfate pro-
teoglycans (AAV2 (4), AAV6 (11)), whereas others utilize sialic
acid for cell surface binding and entry (AAV4 (16), AAV5 (10),
AAV1/6 (11), bovine AAV (17)).
Sialylated glycans that serve as primary receptors for the lat-
ter AAV strains vary at the level of N-acetylneuraminic acid
linkage to underlying sugars, i.e. 2–3 or 2–6 linked to galac-
tose residues (11, 16). Further receptor specificity has been
demonstrated at the level of N-linked or O-linked glycans dis-
played on the cell surface (11, 16). Selective recognition of such
linkages and underlying core glycan types (18) is likely enabled
by differences in the capsid surface topology of AAV serotypes
(19, 20). In general, dependence ofAAV infectivity on sialic acid
has been demonstrated using a battery of chemical, biochemi-
cal, and genetic tools to desialylate cell surface glycans. The
current study is focused on glycan interactions of a humanAAV
isolate, AAV serotype 9/Hu.14 (Clade F) (21). Recombinant
AAV9 vectors display widespread and robust transduction fol-
lowing systemic administration in animal models but fail to
infect cells in culture (21, 22). We demonstrate that efficient
gene transfer by AAV9 vectors requires an atypical interaction
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herein provide amolecular basis for the low infectivity of AAV9
observed in cell culture.
MATERIALS AND METHODS
Plasmids and Viruses—All plasmids were obtained from the
University of North Carolina (UNC) vector core. The triple
plasmid transfection protocol (23) utilized for production of
AAV9 vectors includes (i) the AAV helper plasmid, pXR9, con-
taining AAV2 Rep and AAV9 Cap genes; (ii) the adenoviral
helper plasmid, pXX6-80; and (iii) the vector genome cassette,
pTR-CBA-Luc or pHpa-trs-SK, containing the firefly luciferase
gene driven by the chicken -actin (CBA) promoter or self-
complementary GFP cassette driven by the cytomegalovirus
(CMV) promoter, respectively. The vector genome cassette is
flanked by inverted terminal repeats required for packaging.
The inverted terminal repeats are the only elements within the
vector genome cassette derived from the wild-type AAV
genome, thereby eliminating 96% of viral elements. Recombi-
nant AAV9 vectors generated thus allow quantitation of viral
infectivity (or transduction efficiency) through luciferase trans-
gene expression assays. HEK293 cells utilized for production of
recombinant AAV9 vectors were obtained from the UNC vec-
tor core. Sonicated cell lysates and PEG8000 precipitates from
supernatant were pooled and subjected to cesium chloride
ultracentrifugation as described earlier (23). Dialyzed peak
fractions were subjected to quantitative PCR using a Roche
Light Cycler instrument with luc transgene-specific primers to
determine viral vector titers (forward, 5-AAAAGCACTCTG
ATT GAC AAA TAC-3; reverse, 5-CCT TCG CTT CAA
AAA ATG GAA C-3).
Cell Lines—All cell lines were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin,
streptomycin, amphotericin B (Sigma) and maintained in 5%
CO2 at 37 °C unlessmentioned otherwise. COS-1 (monkey kid-
ney), Neuro2a (mouse neuroblastoma), U87 (human glioma)
and Huh7 (human hepatocarcinoma) cells were obtained from
theUNC tissue culture facility and utilized in viral transduction
assays. Chinese hamster ovary (CHO) Pro5 and mutant Lec1,
Lec2 cell lines were a gift fromDr. Jude Samulski (UNCChapel
Hill), and theCHOLec8 cell linewas purchased fromAmerican
Type Culture Collection. All CHO cells, utilized for viral bind-
ing and transduction assays, were cultured in-MEM (GIBCO)
supplemented with 10% FBS and penicillin, streptomycin, and
amphotericin B as outlined above. Well differentiated human
airway epithelial (HAE) cultures (4–6weeks) grown on perme-
able membrane supports (Millipore, Corning, NY) at the air-
liquid interface were provided by the Cell CultureModels Core
and the UNC Cystic Fibrosis/Pulmonary Research Center.
Transduction Assays—Different cell lines were seeded at 105
cells/well in 24-well plates and allowed to adhere overnight at
37 °C. Plates were then prechilled at 4 °C for 30 min and incu-
batedwithAAV9 vectors at amultiplicity of infection (m.o.i.) of
1000 vector genomes (vg)/cell to allow binding to the cell sur-
face for 1.5 h at 4 °C. Unbound virions were then removed by
washing three times with ice-cold 1 phosphate-buffered
saline (1PBS), and 0.5ml ofDMEMadded to eachwell. Lucif-
erase transgene expression levels were quantitated after incu-
bation for 24 h from cell lysates using a Victor 2 luminometer
(PerkinElmer Life Sciences). For studies with HAE, well differ-
entiated cultures were pretreated with 1.25 units/ml sialidase A
(Prozyme GK80040) at 37 °C for 3 h followed by three washes
with ice-cold 1 PBS. Cultures were then incubated with
scAAV9-CMV-GFP vectors (m.o.i.  105 vg/cell) as outlined
above. Fluorescence micrographs of green fluorescent protein
(GFP) expression inHAE cultures at 2 weeks after transduction
were obtained using an Olympus epifluorescence microscope
equipped with a 20 objective and a Hamamatsu camera.
Enzymatic Desialylation Assays—Different cell lines were
treated with heparinase I and III (from Flavobacterium hepari-
num; Sigma H2519 and H8891), chondroitinase ABC (from
Proteus vulgaris; Sigma C2905), and neuraminidase type III
(from Vibrio cholerae; Sigma N7885) to determine the role of
cell surface glycans in AAV9 infection. Briefly, COS-1 cells
were seeded at 105 cells/well in 24-well plates and pretreated
with 50 milliunits/ml neuraminidase, 3 units/ml heparinase I,
1.5 units/ml heparinase III, and 1.5 units/ml chondroitinase
ABC in DMEM at 37 °C for 2 h. Neuro2a, U87, HEK293, and
Huh7 cells were treated with neuraminidase alone. Cells were
then washed three times with 1 PBS and subjected to AAV9
infection at an m.o.i. of 1000 vg/cell. Luciferase transgene
expression assays were carried out as described earlier at 24 h
after infection.
Chemical Inhibition Assays—CHO Lec2 cells were seeded at
105 cells/well in 24-well plates and pretreated for 24 h with
smallmolecule inhibitors of glycosylation, Swainsonine (10M;
Sigma S8195) and-benzyl-GalNAc (1g/ml; Sigma B4894) to
determine the role of N- and O-glycans in AAV9 infection.
Cells pretreated with chemicals were subjected to AAV9 infec-
tion at anm.o.i. of 1000 vg/cell and luciferase transgene expres-
sion assays carried out as described earlier.
Enzymatic Resialylation Assays—The sialic acid-deficient
cell line, CHO Lec2 was treated with 50 milliunits/ml each of
2,3-(N)-sialyltransferase (Calbiochem 566218), 2,6-(N)-sial-
yltransferase (Calbiochem 566222), or 2,3-(O)-sialyltransfer-
ase (Calbiochem 566227) and 1 mM CMP-sialic acid (Sigma) in
medium for 3 h at 37 °C.UntreatedCHOPro5 cells with endog-
enous sialic acid were included as control. Cells were then
rinsed three times with 1 PBS and subjected to AAV9 infec-
tion at anm.o.i. of 1000 vg/cell and luciferase transgene expres-
sion assays carried out as described earlier.
Lectin Inhibition and Staining Assays—Competitive inhibi-
tion of AAV9 infection was carried out using a panel of lectins,
concanavalin A (ConA), wheat germ agglutinin (WGA),
Maackia amurensis lectin (MAL I), Sambucus nigra lectin
(SNA), and Erythrina cristagalli lectin (ECL) obtained from
Vector Laboratories (Burlingame, CA). Briefly, prechilled CHO
Pro5 or mutant Lec2 cells were incubated with 100 g/ml
FITC-conjugated lectin (fluorescent labeling assay) in -MEM
or along with AAV9 particles (transduction assay at m.o.i. 
10,000 vg/cell) for a period 1.5 h at 4 °C. After threewasheswith
ice-cold 1 PBS to remove unbound virions and/or lectins,
cells were imaged using an Olympus epifluorescence micro-
scope equipped with a Hamamatsu camera or incubated for
24 h at 37 °C prior to luciferase transgene expression analysis.
Cell Surface Binding Assays—CHO Pro5 cells were seeded at
a density of 104 cells/well in 96-well plates prior to treatment
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with 50 milliunits/ml neuraminidase type III from V. cholerae
for 2 h at 37 °C. Untreated Pro5 and Lec2 cells were included as
negative and positive controls, respectively. Cells were then
prechilled at 4 °C for 30min, followed by incubationwithAAV9
particles at m.o.i. of 102, 5 102, 103, 5 103, 104, 5 104, 105,
5  105 vg/cell for 1.5 h at 4 °C. Cells were then subjected to
three washes with ice-cold 1 PBS to remove unbound virions.
Cell surface-bound virionswere collected alongwith cell lysates
following three freeze-thaw cycles and vg copy numbers/cell
determined using quantitative PCR as outlined earlier. Binding
curves were generated using GraphPad Prism 5 software by
applying the single site binding model (Y  Bmax*X/(Kd  X)),
where Y represents the number of bound virions/cell deter-
mined by quantitative PCR; X represents m.o.i.; Bmax is the
maximum binding capacity, and Kd, the observed disassocia-
tion constant.
Animal Studies—All experiments were carried out with
6–8-week old female BALB/c mice (Jackson Laboratories, Bar
Harbor, ME) maintained and treated in accordance with
National Institutes of Health guidelines and as approved by
IACUC at UNC-Chapel Hill. Mice were administered via intra-
nasal instillationwith either 100l of PBS (50l/nostril) or 100
l of neuraminidase type III from V. cholerae (200 milliunits;
Sigma). At 2 h after treatment, a dose of 5  1010 AAV9 parti-
cles in 1 PBS (50 l/nostril) was administered. Luciferase
transgene expression in live animals was obtained using a
Xenogen IVIS Lumina imaging system (Caliper Lifesciences,
CA) after intranasal instillation of luciferin substrate (120
mg/kg; Nanolight). Image analysis was carried out using the
Living Image software (Caliper Lifesciences) and luciferase
expression reported in relative light units (photons/s per cm2
per steradian).
RESULTS
Neuraminidase Treatment Selectively Increases AAV9
Transduction in Different Cell Types—Enzymatic removal of
different cell surface glycans was achieved by treating cells with
different glycosidases. Removal of terminal sialic acid residues
using neuraminidase (fromV. cholerae) enhanced AAV9 trans-
duction by 1 log unit compared with virus alone on COS-1
cells (Fig. 1A). In contrast, hydrolysis of cell surface heparan
sulfate or chondroitin sulfate proteoglycans using heparinase
I/III or chondroitinase ABC, respectively, had no effect on viral
transduction compared with control. Neuraminidase treat-
ment abrogated AAV1 transduction, whereas AAV2 remained
unaffected under these conditions (Fig. 1B). In addition, treat-
ment of cell lines derived from different tissues with neuramin-
idase (gray bars) prior to AAV9 infection enhanced transduc-
tion efficiency by nearly 2 log units in contrast to infection with
virus alone (white bars) (Fig. 1C). These results were corrobo-
rated by increased binding and internalization ofAAV9, but not
AAV1 vectors upon sialidase treatment in these cell lines (sup-
plemental Figs. S1 and S2). Thus, sialic acid appears tomask cell
surface glycans that selectively facilitate AAV9 infection in
vitro. Further, enzymatic desialylation might serve as a facile
biochemical strategy to enhance transduction efficiency of
AAV9 vectors in vitro and might enable detailed analysis of
intracellular trafficking pathways.
Mutant CHO Lec2 Cells Lacking Terminal Sialic Acid Are
Highly Permissive to AAV9 Infection—Analysis of cell surface
binding and infectivity of AAV1 and AAV9 on parental (Pro5)
and mutant CHO cell lines was carried out to further under-
FIGURE 1. Effect of enzymatic desialylation on AAV9 transduction. A, dif-
ferent enzymes (heparinase I (HepI), heparinase III (HepIII), neuraminidase
from V. cholerae (Neu) and chondroitinase ABC (ChABC)) were utilized to
deglycosylate prominently expressed cell surface glycans on COS-1 cells.
Transduction assays with AAV9 vectors (m.o.i.  1000 vg/cell) were carried
out 2 h after enzymatic treatment. B, neuraminidase treatment of COS-1 cells
prior to infection with AAV1, AAV2, or AAV9 vectors (m.o.i.  1000 vg/cell)
was carried out to demonstrate serotype selective effects of enzymatic desia-
lylation on transduction efficiency. C, different cell lines (HEK293, U87, Huh7,
and Neuro2a) were untreated (white bars) or pretreated with neuraminidase
from V. cholerae (gray bars) followed by subsequent infection with AAV9 vec-
tors (m.o.i.  1000 vg/cell). Luciferase transgene expression (relative light
units, RLU) was quantified for both studies at 24 h after infection. All experi-
ments were carried out in triplicate. Error bars represent S.E.
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stand the role of core glycans under sialic acid in AAV9 infec-
tion. The CHO Lec2 cell line lacks terminal sialic acid due to a
defect inCMP-sialic acid transport (24), whereas Lec8 andLec1
cell lines are defective in translocation of UDP-galactose and
N-acetylglucosaminyl transferase activity (25, 26), respectively.
Correspondingly, cell surface glycans on CHO Lec2 cells con-
tain terminal galactosyl residues, whereas Lec8 and Lec1 cell
lines display predominantly terminalN-acetylglucosamine and
mannosylated glycans, respectively (Fig. 2A). As seen in Fig. 2,B
and C, cell surface binding and transduction of AAV9 particles
(gray bars) on Lec2 cells are significantly increased (1 log
unit) compared with the parental Pro5 cell line. In contrast,
AAV1 (white bars), which requires sialic acid for infection,
shows 10-fold decrease in binding and transduction in all
CHO Lec mutant cell lines. In addition, no major changes in
binding and infectivity are observed in case of Lec8 and Lec1
cells for AAV9 particles. These results suggest that galactosy-
lated glycans immediately underlying sialic acid can facilitate
AAV9 cell surface binding and entry. The results also support
the notion that AAV9 particles might exploit an inefficient and
nonspecific uptakemechanism in the parental Pro5 andmutant
Lec8 and Lec1 cell lines.
Sialylation of N-Linked Glycans Blocks AAV9 Infection—To
elucidate the nature of glycans required for AAV9 infection
further, we utilized small molecule inhibitors of glycosylation
and sialyltransferases to modify terminal galactosyl residues on
the sialic acid-deficient Lec2 cell surface. Swainsonine (27) and
-benzyl-O-GalNAc (28) are chemical inhibitors of N-linked
andO-linked glycosylation, respectively. Treatment with these
reagents results in a corresponding decrease in cell surface
expression ofN-linked glycans andO-linked glycans. As seen in
Fig. 3A, AAV9 infection is significantly blocked by Swainsonine
( 75%), whereas -benzyl-O-GalNAc has a modest inhibitory
effect (25%). These results suggest that AAV9 prefers N-
linked cell surface glycans for infection. In addition, resialyla-
tion of the sialic acid-deficient Lec2 cell surface was carried out
to understand the nature of the sialic acid linkage that blocks
AAV9 infection (Fig. 3B). The abilities of different sialyltrans-
ferases to partially blockAAV9 infectionwas observed to follow
the order 2,3-N-sialyltransferase (3NST)  2,6-N-sialyl-
transferase (6NST) 2,3-O-sialyltransferase (3OST). Alter-
ation of cell surface glycans upon resialylation was confirmed
by staining with lectins recognizing different glycan residues
and linkages (Fig. 3C). As expected Pro5 cells expressing sialy-
lated glycans and Lec2 cells expressing asialoglycans demon-
strate preferential staining by FITC-MAL I and FITC-ECL,
respectively. Resialylation of Gal(1,4)GlcNAc residues with
3NST, but not 3OST partially restores FITC-MAL-I staining
concurrent with decrease in AAV9 transduction. The lack of
MAL I staining in 6NST-treated Lec2 cells is expected due to
lack of recognition of 2,6-sialylated glycans by MAL I. Taken
together, these results not only corroborate the important role
played by coreN-linked glycans in AAV9 infection, but also the
potential for2,3 and2,6 sialic acid linkages to block infection
by masking underlying glycoconjugates on the cell surface.
TerminalGalactosyl Residues Are Critical for AAV9 Infection—
To understand better the nature of AAV9-glycan interactions
that mediate infection, we carried out competitive inhibition
studies with lectins that recognize different glycan linkages on
the cell surface (Fig. 4, A and B). Specifically, we utilized (i)
MAL I, which recognizes native,2,3-sialylated, or sulfated gly-
coconjugates having Gal(1,4)N-GlcNAc structures (29, 30);
(ii) SNA lectin, which binds preferentially to 2,6-sialylated
galactose residues (31); (iii) ECL, which demonstrates specific-
FIGURE 2. Effect of glycan chain composition on cell surface binding and
transduction of AAV9. A, schematic representation of N-glycan composi-
tions of the parental CHO Pro5 cell line and mutants Lec2, Lec8 and Lec1 (36)
using nomenclature proposed by the Consortium for Functional Glycomics
nomenclature committee (F, mannose; f, GlcNAc; E, galactose; , sialic
acid) is shown. B, binding of AAV1 (white bars) and AAV9 (gray bars) particles
to wild-type and parental CHO cell lines was analyzed using quantitative PCR
as described under “Materials and Methods.” The number of bound virions is
expressed as vg/cell. C, transduction efficiency (relative light units, RLU) of
AAV1 (white bars) and AAV9 (gray bars) particles (m.o.i.  1000 vg/cell) on
parental and mutant CHO cell lines was analyzed by quantifying luciferase
transgene expression at 24 h after infection. All binding experiments were
carried out in quadruplicate and infectivity assays in triplicate. Error bars rep-
resent S.E.
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ity toward galactose residues, in particular, Gal(1,4)N-
GlcNAc (32); (iv) WGA, which binds N-GlcNAc and tolerates
glycoconjugates containing sialic acid with different linkages
(33); and (v) ConA, which recognizes mannose residues (34).
The SNA lectin had no effect on AAV9 infection and can be
explained by low levels of 2,6-sialylated glycans in both cell
lines of rodent (hamster) origin (35). On the other hand, the
MAL I demonstrated 5–10-fold inhibition ofAAV9 infection in
both Pro5 and Lec2 cell lines. More importantly, a striking dif-
ference in AAV9 transduction was observed in case of ECL-
treated cells with 5-fold inhibition in parental Pro5 cells and
nearly 200-fold inhibitory activity in the Lec2 cell line, demon-
strating the importance of core Gal1-linked residues. The
ConA andWGA lectins demonstrated broad inhibitory activity
in both parental Pro5 cells and the sialic acid-deficient Lec2 cell
line suggesting that underlying N-GlcNAc and core mannose
residues might contribute to AAV9-glycan interactions.
These results were corroborated by fluorescent staining of
Pro5 and Lec2 cell lines with aforementioned lectins (Fig. 4C).
As expected, MAL I andWGA lectin, which bind to 2,3-sialy-
lated glycans, preferentially label Pro5 cells. In contrast, prefer-
ential ECL staining is noted in Lec2 cells. The SNA lectin, which
recognizes 2,6-sialic acid, does not stain either Pro5 or Lec2
cells, confirming the lack (or modest expression) of 2,6-sialy-
lated glycans on these hamster-derived cell lines. Further evi-
dence supporting the important role of galactose in mediating
AAV9 infection was obtained by treatment of CHO Pro5 cells
with endo--galactosidase (supplemental Fig. S3, A and B).
Removal of galactose residues, but not fucose abrogated AAV9
transduction. Taken together, these results suggest that termi-
nal galactosyl residues serve as the primary receptor for AAV9.
Desialylation Increases the Cell Surface Binding Potential of
AAV9 Particles—Cell surface binding curves were generated to
establish a quantitative biochemical rationale for the observed
increase in AAV9 transduction following desialylation. Binding
of AAV9 particles to the surface of parental CHO Pro5 cells,
sialidase-treated Pro5 cells, or sialic acid-deficient Lec2 cells
was carried out over a range of multiplicities of infection (vg/
cell). As seen in Fig. 5, enzymatic removal of sialic acid partially
recapitulates the effect of genetic desialylation by increasing
the number of cell surface-bound AAV9 particles. Nonlinear
regression analyses of binding data were carried out using the
single site binding model (Y  Bmax*X/(Kd  X)), where X and
Y represent multiplicity of infection and number of bound
AAV9 particles, respectively; Bmax is the maximum binding
capacity, andKd is the relative (observed) binding affinity. Cal-
culation of aforementioned parameters reveals Bmax values
averaging 375 vg/cell on wild-type Pro5 cells, a 3-fold
increase to 1025 vg/cell on sialidase-treated Pro5 cells, and a
5-fold increase to 1971 vg/cell on the sialic acid-deficient
FIGURE 3. A, effect of glycosylation inhibitors on AAV9 transduction. Prior to infection with AAV9 vectors (m.o.i.  1000 vg/cell), CHO Lec2 cells were treated
with -benzyl-GalNAc (1 g/ml) or Swainsonine (10 M), inhibitors of O- and N-glycosylation, respectively. B, effect of enzymatic resialylation on AAV9
transduction. CHO Lec2 cells were treated with 50 milliunits/ml each of 2,3-(N)-sialyltransferase (2,3NST), 2,6-(N)-sialyltransferase (2,6NST), or 2,3-(O)-
sialyltransferase (2,3OST) and 1 mM CMP-sialic acid (Sigma) to resialylate cell surface asialo glycans. Luciferase transgene expression was quantified at 24 h
after infection and is expressed as percent infectivity with respect to untreated or wild type (CHO Pro5) control. All experiments were carried out in triplicate.
Error bars indicate S.E. C, lectin staining of CHO cell lines subjected to enzymatic resialylation. CHO Lec2 cells treated with CMP-sialic acid alone or with
CMP-sialic acid and different sialyltransferases were subjected to lectin staining using FITC-labeled ECL, which exclusively recognizes Gal(1,4)GlcNAc or
FITC-labeled MAL, which recognizes 2,3-sialylated Gal(1,4)GlcNAc. Untreated wild-type CHO Pro5 cells, which show high levels of FITC-MAL I staining and
untreated Lec2 cells, which show high levels of FITC-ECL staining, were included as control.
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Lec2 cell line. These results support the observation that AAV9
prefers asialo N-glycans with terminal Gal1-linked residues.
In addition, an apparent decrease in Kd (3-fold) is observed
in Lec2 cells as well as a corresponding 15-fold increase in rel-
ative binding potential (Bmax/Kd) (Table 1). These results sup-
port the notion that enhanced avidity plays a role in mediating
AAV9 binding to asialo N-glycans.
Sialidase Pretreatment Increases AAV9 Gene Transfer Effi-
ciency in HAE and Murine Airways—To evaluate the potential
of enzymatic desialylation as a strategy to enhance gene transfer
by AAV9 vectors, we evaluated the effect of sialidase pretreat-
ment on AAV9 transduction efficiency in well differentiated
HAE cultures and murine airways. A marked increase in GFP-
positive HAE was observed upon treatment with neuramini-
dase from Arthrobacter ureafaciens (recombinant sialidase A)
prior to infection with scAAV9/CMV-GFP vectors (Fig. 6, A
and B). Further, quantitation of live animal bioluminescent
images of BALB/cmice following intranasal instillation of siali-
dase showed 10-fold increase in luciferase transgene expres-
sion in murine airways mediated by AAV9/CBA-Luc vectors
(Fig. 6,C andD and supplemental Fig. S4). These results further
validate the role of asialoN-glycans as the primary receptor for
AAV9 in mouse and human species as well as provide a novel
adjuvant strategy to enhance AAV9 gene transfer.
DISCUSSION
Glycomic profiles ofmajorN-andO-glycans expressed in the
parental CHO Pro5 and the CHO Lec2 mutant (35, 36) were
instrumental toward delineating the nature of glycans that play
a role in cell surface binding and infection by AAV9 vectors.
The N-glycan profile of CHO Pro5 cells has been shown to
possess complex bi-, tri-, and tetra-antennary structures
bearing multiple N-acetyllactosamine (LacNAc) extensions,
capped with sialic acid (NeuAc) residues. In addition, the
O-glycan profile contains Gal(1,3)GalNAc core structures
that are mono- or disialylated. In contrast, the most abun-
dant glycans produced by the sialic acid-deficient Lec2 cell
line are asialo N-glycans, possessing between 2 and 7 Lac-
NAc units. The O-glycan profile is known to be similarly
affected by altered sialylation (36). These observations sug-
gest that LacNAc units might serve as cell surface attach-
ment factors for AAV9. Treatment of the Lec2 cell line with
chemical inhibitors and sialyltransferase enzymes confirmed
that Gal1-linked N-glycans rather than O-glycans were the
preferred substrate for attachment. These results were fur-
ther corroborated by competitive inhibition studies with the
LacNAc-specific ECL. In addition, ConA and WGA lectins
revealed a potential contributing role for mannose and
GlcNAc residues underlying terminal galactose in mediating
AAV9 infection. Further evidence supporting the aforemen-
tioned results was also obtained from competitive inhibition
studies of AAV9 particles co-incubated with different glycan
residues. Although only a modest inhibitory effect was
observed potentially due to low affinity interactions, mono-
meric LacNAc (LN) units, but not 2,3-sialylated LN (3-
SLN) or 2,3-sialylated di-LN (3-S-Di-LN) glycans appear
to block AAV9 infection selectively (supplemental Fig. S5).
FIGURE 4. Effect of lectin competition on AAV9 transduction. A and B, wild-type CHO Pro5 (A) and sialic acid-deficient Lec2 (B) cell lines were co-incubated
with lectins recognizing different glycan linkages (100 g/ml) and AAV9 vectors (m.o.i.  10,000 vg/cell). Briefly, ConA lectin recognizes mannose residues,
whereas WGA lectin recognizes GlcNAc residues as well as sialic acid residues. MAL and SNA lectins recognize 2,3- and 2,6-linked sialic acid residues,
respectively, whereas ECL exclusively recognizes Gal(1,4)GlcNAc residues. Luciferase transgene expression (percent transduction) was quantified at 24 h after
infection. All experiments were carried out in triplicate. Error bars represent S.E. C, lectin staining of Pro5 and Lec2 cell lines was carried out using FITC-labeled
lectins, and fluorescent images were obtained as described under “Materials and Methods.”
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Cell surface binding studies constitute a direct approach to
determine the relative binding potential (Bmax/Kd) of AAV9
particles under physiological conditions. Upon desialylation,
the observed increase in number of binding sites (Bmax) is likely
due to increased availability of asialoN-glycans on the cell sur-
face. The increase in relative binding affinity (Kd) is potentially
a consequence of the increased number of binding sites and can
be explained by enhanced avidity arising from multivalent
interactions. The aforementioned results suggest that the rela-
tively low abundance of asialo N-glycans provides a molecular
basis for the low transduction displayed by AAV9 in cell cul-
ture. In contrast to in vitro assays, studies in rodent, canine, and
primatemodels have demonstrated robust andwidespread sys-
temic gene transfer using AAV9 vectors following intravenous
administration (22, 37, 38). As such, the nature of AAV9-glycan
interactions does not provide sufficient rationale for the
observed lack of in vitro-in vivo correlation outlined above. As
seen in case of other viruses, potential interactions with blood
components (39) or co-receptors such as integrins (40) might
play an important role in dictating the transduction profile
observed in animalmodels. Nevertheless, it is tempting to spec-
ulate that the relative abundance of asialo N-glycans in various
animal tissues likely contributes to the broad biodistribution
pattern and tissue tropism displayed by AAV9 vectors in vivo.
Studies with animal models lacking sialyltransferases (41, 42)
might provide further insight into the mechanism(s) underly-
ing tissue tropism displayed by AAV9.
Carbohydrate receptors utilized by members of different
AAV clades appear to fall under two classes, namely, heparan
sulfate proteoglycans and sialylated glycans (43). For instance,
AAV2, aClade Bmember, utilizes heparan sulfate proteoglycan
as a primary receptor (4). The closely related strains, AAV1 and
AAV6 of Clade A, appear to equally prefer 2,3- and 2,6-N-
linked sialic acid for infection (11). Further, AAV6 has been
shown to bind heparin, implying a potential dual mechanism of
interaction with cell surface glycans (44). Serotypes AAV4 and
AAV5, which have not been assigned to any clade thus far,
require 2,3-O- and 2,3-N-linked sialic acid for cell surface
binding, respectively (16). The current study identifies a third
class of glycan receptors with terminal galactose utilized by the
AAV strain Hu.14/AAV9 for infection. The latter serotype has
been classified under Clade Fwithin the AAVphylogenetic tree
(21). The major capsid protein (VP3, viral protein subunit 3) of
other AAV isolates within Clade F is largely similar to Hu.14/
AAV9 (GenBank accession number AY530579.1). Specifically,
isolate Hu.31 (GenBank accession number AY530596.1) differs
from Hu.14/AAV9 by 2 amino acid residues (S386G, N716S),
whereas the VP3 subunit of isolate Hu.32 (GenBank accession
numberAY530597.1) is identical toHu.14/AAV9.These obser-
vations suggest that at least one other member of Clade F
(Hu.32) might utilize nonsialylated glycans for cell surface
binding and entry. Finally, Akache et al. (45) have previously
reported the role of laminin receptor (LamR) in mediating
transduction by AAV9.Whether the 2.5-fold increase in AAV9
transduction mediated by LamR in the previous report within
transfected NIH 3T3 cells is due to enhanced binding or inter-
nalization is unknown. Nevertheless, low levels of LamR
expressed in CHO cells (46) might account for residual trans-
duction of AAV9 seen in the current study.
Recombinant sialidase has been proposed as a therapeutic
agent in several clinical modalities. For instance, a sialidase
fusion protein has been proposed as an antiviral agent for pro-
tection from influenza viruses (47, 48). The latter approach
hinges on the inhibition of cell surface binding by influenza
viruses due to desialylation of cell surface glycans. In another
recent study, intrathecal infusion of recombinant sialidase,
which reverses inhibition of axon outgrowth in neurons, has
been proposed as a candidate therapy for spinal cord injury
(49). In the current study, enzymatic desialylation was found to
markedly enhance binding and transduction of AAV9 across
FIGURE 5. Effect of desialylation on cell surface binding of AAV9 particles.
Sialic acid-deficient Lec2 cells (f), untreated wild-type Pro5 cells (F), and
sialidase-treated Pro5 cells (E) were prechilled and incubated with AAV9 par-
ticles at different m.o.i. ranging from 100 to 500,000 (across 4.5 orders of
magnitude) at 4 °C to allow binding, without cellular uptake. Quantitative
analysis of dose-dependent AAV9 binding to cell surface asialo N-glycans was
carried out by generating binding curves using a single-site binding model as
described under “Materials and Methods.” Inset shows linear range of the
binding curve from x axis values ranging from 100 to 10,000 vg/cell. Calcu-
lated binding parameters are listed in Table 1. All experiments were carried
out in triplicate. Error bars represent S.E.
TABLE 1
Binding parameters for AAV9 interactions with cell surface glycans
Parameters Pro5 Pro5  Sialidase Lec2
Bmax (vg/cell) 3.75  102  0.86  102 1.03  103  0.19  103 1.97  103  0.25  103
Kd (vg/cell) 3.58  105  1.64  105 3.34  105  1.26  105 1.22  105  0.41  105
Bmax/Kd 1.05  103 3.07  103 1.62  102
R2 0.97 0.96 0.96
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different cell types regardless of host or tissue type. In addition,
intranasal instillation of sialidase markedly enhanced gene
transfer efficiency of AAV9 in murine airways supporting the
potential application of recombinant sialidase as an adjuvant in
therapeutic gene transfer applications in the lung/airways. Spe-
cifically, co-administration or pretreatment of different tissue
types such as the lung, central nervous system, or eye with
recombinant sialidase might serve as (i) a strategy to expose
high avidity glycan receptors and consequently restrict AAV9
transduction to these specific tissue types; (ii) a facile biochem-
ical strategy to increase gene transfer efficiency of AAV9 vec-
tors; and (iii) amethod to evaluate AAV9 vectors in desialylated
preclinical models eliminating cross-species variation in sialy-
lation patterns.
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